Lu Xiaoling's role career

As the first person in charge, he presided over the project 10, including 7 national projects; He has participated in major international cooperation projects of the Ministry of Science and Technology, 863 projects of the Ministry of Science and Technology, 973 projects and key doctoral programs of the "985 Project". In recent years, the first author/* * * and the first author or correspondent have published 23 research papers, including SCI papers 16 and 3 invention patents. Participated in international academic conferences for many times and reported academic papers at the conference. Instruct five master students. Research topic under study: 1. The National Natural Science Foundation of China supported the project of 650,000 yuan: The anti-tumor research of the bifunctional fusion protein targeting specific CD8+CD28+CTL at Endoglin-scFv/IP 10, which is in progress. 2. National Natural Science Foundation Project of 390,000 yuan (including corresponding supporting facilities): Anti-tumor research on targeted recruitment of CTL by Endoglin aptamer /IP- 10 bioreactor, responsible and in progress. 3. National Natural Science Foundation of China Youth Fund Project 200,000: A new method of amplifying tumor-specific CTL based on antibody-mediated aAPC and MHC/ antigenic peptide tetramer for tumor treatment, responsible and in progress. 4. The Ministry of Education supports 500,000 yuan of outstanding talents in the new century: Endoglin-scFv/IP- 10. The research on the anti-tumor effect and mechanism of bifunctional molecules targeting molybdenum-specific T cells is under way. 5. The key scientific and technological research project of the Ministry of Education is 654.38+10,000 yuan (including the corresponding supporting facilities): endorglin-ScFv/IP- 10 bifunctional molecules enhance the anti-tumor effect of DC vaccine and study on its mechanism. The person in charge is in progress. 6. Guangxi Innovation Research Team Project: 2.4 million yuan (including corresponding funds): theoretical and applied research on ultra-acute rejection anti-tumor vaccine, second leader, in progress. 7. Guangxi Science and Technology Plan Project 70,000 yuan: Mannose-modified CS-PCL particles loaded with tumor antigen directionally enhance the anti-tumor effect of DC, responsible and in progress. 8. Guangxi University Excellent Talents Funding Program Project 30,000: Screening of tumor vascular specific molecule Endoglin aptamer, responsible, in progress. 9. Guangxi Medical University Talent Introduction Fund Project 654.38+00,000 yuan: Research on tumor biological targeted therapy, responsible, in progress.